과제정보
This research was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. NRF-2016R1A6A1A03011325) and Ministry of Science and ICT (MSIT) (No. NRF-2022R1A2C1008787).
참고문헌
- Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535-554. https://doi.org/10.1016/S0140-6736(21)00312-3
- Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012;7:924-933. https://doi.org/10.1097/JTO.0b013e31824cc334
- Dong J, Li B, Lin D, Zhou Q, Huang D. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. 2019;10:230.
- Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23:781-783. https://doi.org/10.1101/gad.1787609
- Luo J, Huang Z, Wei W, Sun Y, Gong Y. Editorial: epigenetic regulation and non-histone post-translational modification in cancer. Front Genet. 2023;14:1176174.
- Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012;4:5.
- Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011;2011:875824.
- Wang Z, Tang F, Hu P, Wang Y, Gong J, Sun S, Xie C. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep. 2016;36:589-597. https://doi.org/10.3892/or.2016.4811
- Pulya S, Amin SA, Adhikari N, Biswas S, Jha T, Ghosh B. HDAC6 as privileged target in drug discovery: a perspective. Pharmacol Res. 2021;163:105274.
- Dong J, Zheng N, Wang X, Tang C, Yan P, Zhou HB, Huang J. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer. Eur J Pharmacol. 2018;828:67-79. https://doi.org/10.1016/j.ejphar.2018.03.026
- Li J, Yu M, Fu S, Liu D, Tan Y. Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front Pharmacol. 2022;13:907981. Erratum in: Front Pharmacol. 2022;13:1117936.
- Park SJ, Joo SH, Lee N, Jang WJ, Seo JH, Jeong CH. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Arch Pharm Res. 2021;44:1062-1075. https://doi.org/10.1007/s12272-021-01359-x
- Zhang XH, Kang HQ, Tao YY, Li YH, Zhao JR, Ya-Gao, Ma LY, Liu HM. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. Eur J Med Chem. 2021;218:113392.
- Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle. 2008;7:2090-2096. https://doi.org/10.4161/cc.7.14.6324
- Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-inducible factors and cancer. Curr Sleep Med Rep. 2017;3:1-10. https://doi.org/10.1007/s40675-017-0062-7
- Kurtipek E, Kocak N, Esme H, Duzgun N, Akin SE, unlu Y, Bekci TT. The role of HIF-1 pathway in non-small-cell lung cancer. Eur Respir J.2016;48:PA2855.
- Zhu J, Huang Z, Zhang M, Wang W, Liang H, Zeng J, Wu K, Wang X, Hsieh JT, Guo P, Fan J. HIF-1α promotes ZEB1 expression and EMT in a human bladder cancer lung metastasis animal model. Oncol Lett. 2018;15:3482-3489. Erratum in: Oncol Lett. 2021;22:599.
- Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001;15:2445-2453. https://doi.org/10.1096/fj.01-0125com
- Cao Y, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, Nien CY, Hanna G, Rich JN, Provenzale JM, Dewhirst MW. Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res. 2013;73:6230-6242. https://doi.org/10.1158/0008-5472.CAN-12-1345
- Ryu HW, Won HR, Lee DH, Kwon SH. HDAC6 regulates sensitivity to cell death in response to stress and post-stress recovery. Cell Stress Chaperones. 2017;22:253-261. https://doi.org/10.1007/s12192-017-0763-3
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408. https://doi.org/10.1006/meth.2001.1262
- Zhang Q, Zhang ZF, Rao JY, Sato JD, Brown J, Messadi DV, Le AD. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer. 2004;111:849-857. https://doi.org/10.1002/ijc.20334
- Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5:378-389. https://doi.org/10.1016/j.apsb.2015.05.007
- Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, Engel P, Postigo A. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010;29:3490-3500. https://doi.org/10.1038/onc.2010.102
- Haase VH. The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des. 2009;15:3895-3903. https://doi.org/10.2174/138161209789649394
- Li T, Mao C, Wang X, Shi Y, Tao Y. Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation. J Exp Clin Cancer Res. 2020;39:224.
- Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle. 2006;5:2430-2435. https://doi.org/10.4161/cc.5.21.3409
- Yoo YG, Kong G, Lee MO. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J. 2006;25:1231-1241. https://doi.org/10.1038/sj.emboj.7601025
- Seo HW, Kim EJ, Na H, Lee MO. Transcriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1. FEBS Lett. 2009;583:55-60. https://doi.org/10.1016/j.febslet.2008.11.044
- Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006;26:2019-2028. https://doi.org/10.1128/MCB.26.6.2019-2028.2006
- Geng H, Liu Q, Xue C, David LL, Beer TM, Thomas GV, Dai MS, Qian DZ. HIF1α protein stability is increased by acetylation at lysine 709. J Biol Chem. 2012;287:35496-35505. https://doi.org/10.1074/jbc.M112.400697
- Saito S, Zhuang Y, Shan B, Danchuk S, Luo F, Korfei M, Guenther A, Lasky JA. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway. PLoS One. 2017;12:e0186615.
- Schoepflin ZR, Shapiro IM, Risbud MV. Class I and IIa HDACs mediate HIF-1α stability through PHD2-dependent mechanism, while HDAC6, a Class IIb member, promotes HIF-1α transcriptional activity in nucleus pulposus cells of the intervertebral disc. J Bone Miner Res. 2016;31:1287-1299. https://doi.org/10.1002/jbmr.2787
- McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. Prostate. 2018;78:266-277. https://doi.org/10.1002/pros.23467
- Yang L, Chang Y, Cao P. CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells. Exp Cell Res. 2018;371:231-237. https://doi.org/10.1016/j.yexcr.2018.08.015
- Wang J, Xu MQ, Jiang XL, Mei XY, Liu XG. Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells. Anticancer Drugs. 2018;29:80-88. https://doi.org/10.1097/CAD.0000000000000573
- Wawruszak A, Kalafut J, Okon E, Czapinski J, Halasa M, Przybyszewska A, Miziak P, Okla K, Rivero-Muller A, Stepulak A. Histone deacetylase inhibitors and phenotypical transformation of cancer cells. Cancers (Basel). 2019;11:148.